- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01091168
Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer
Phase III Trial of IV Vinflunine Versus an Alkylating Agent in Patients With Metastatic Breast Cancer Previously Treated With or Resistant to an Anthracycline, a Taxane, an Antimetabolite, and a Vinca-alkaloid (Study L00070 IN 308 B0)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Breast cancer is the most frequently diagnosed cancer in women worldwide and the second leading cause of cancer-related deaths in women.
Patients with metastatic breast cancer (MBC) remains incurable, and current goals of therapy are to ameliorate symptoms, delay disease progression, improve or at least maintain quality of life (QoL), and prolong overall survival (OS).There are a number of agents with established single-agent activity, with the anthracyclines and taxanes considered generally the most active. In addition, several drugs with different mechanisms of action such as antimetabolites and vinca-alkaloids have also demonstrated substantial activity in the metastatic setting as single-agents or in combination.
In patients who progress after having received anthracyclines, taxanes, antimetabolites and vinca- alkaloids, therapeutic options are scarce. In this heavily pretreated population for whom overall survival is not expected to exceed 6 to 7 months, there is a clear need for novel therapies.
Vinflunine (VFL) is a microtubule inhibitor obtained by semi-synthesis, interacts with tubulin at the vinca-binding domain and inhibits tubulin assembly by perturbing microtubule dynamics and mitotic spindles without affecting assembled microtubules. VFL antitumour activity was fully demonstrated against a large and varied panel of murine and xenograft models.
The main haematological toxicity reported was the neutropenia Grade 3-4 (40-50%). The incidence of its complications (febrile neutropenia and neutropenic infection) was less than 8%. The main non-haematological toxicity Grade 3-4 (with an incidence more than 10%) reported were constipation and fatigue.
This was a prospective multicentre, open-label, randomised (1:1), phase III study comparing OS in patients treated with vinflunine versus those treated with an alkylating agent of physician's choice as third line treatment or more for patients with locally recurrent and/or metastatic breast cancer previously treated with and no longer candidate to anthracyclines, antimetabolites, taxanes and vinca- alkaloids..
The primary endpoint for the trial was OS. Patients were assessed for toxicity, tumour response and progression and status (alive-dead) at regular intervals during the study treatment and the follow-up period. Patients were treated until disease progression, unacceptable toxicity, patient or investigator's decision. After the study treatment discontinuation, patients were followed until death.
The VFL dose of 280 mg/m² was the selected dose for this phase III study in patients with heavily pre- treated MBC. Indeed, VFL dose was reduced from 320 to 280 mg/m² in advanced transitional cell carcinoma of urothelial tract patients with performance status (PS) of 1 or with PS of 0 and having received prior pelvic irradiation. This dose was more regularly tolerable in patients with advanced disease stage who were heavily pre-treated.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Buenos aires, Argentina
-
Quilmes, Argentina
-
Rosario, Argentina
-
San Martin, Argentina
-
Tucuman, Argentina
-
-
-
-
-
Graz, Austria
-
Salzburg, Austria
-
Vienna, Austria
-
-
-
-
-
Gomel, Belarus
-
Grodno, Belarus
-
Minsk, Belarus
-
Vitebsk, Belarus
-
-
-
-
-
Brussels, Belgium
-
Haine Saint Paul, Belgium
-
Yvoir, Belgium
-
-
-
-
-
Angers, France
-
Brest, France
-
Clermont Ferrand, France
-
Dijon, France
-
Grenoble, France
-
Le Mans, France
-
Lille, France
-
Limoges, France
-
Lorient, France
-
Montpellier, France
-
Nancy, France
-
Nantes, France
-
Nice, France
-
Paris, France
-
Pontoise, France
-
Reims, France
-
Rouen, France
-
Saint Brieuc, France
-
Saint Priest en Jarez, France
-
Strasbourg, France
-
-
-
-
-
Berlin, Germany
-
Dortmund, Germany
-
Essen, Germany
-
Mainz, Germany
-
Munich, Germany
-
Trier, Germany
-
-
-
-
-
Ancona, Italy
-
Aviano, Italy
-
Bolzano, Italy
-
Brindisi, Italy
-
Frattamaggiore, Italy
-
Macerata, Italy
-
Orbassano, Italy
-
-
-
-
-
Lisboa, Portugal
-
-
-
-
-
Arkhangelsk, Russian Federation
-
Engels, Russian Federation
-
Moscow, Russian Federation
-
Ryazan, Russian Federation
-
Saratov, Russian Federation
-
St Petersburg, Russian Federation
-
Stavropol, Russian Federation
-
Tambov, Russian Federation
-
Ufa, Russian Federation
-
Volgograd, Russian Federation
-
-
-
-
-
Durban, South Africa
-
Johannesburg, South Africa
-
Pretoria, South Africa
-
-
-
-
-
A coruna, Spain
-
Barcelona, Spain
-
Madrid, Spain
-
Sevilla, Spain
-
-
-
-
-
Taichung, Taiwan
-
Taipei, Taiwan
-
Taoyuan, Taiwan
-
-
-
-
-
Dnipropetrovsk, Ukraine
-
Kharkiv, Ukraine
-
Khmelnytskyi, Ukraine
-
Kyiv, Ukraine
-
-
-
-
-
Burnley, United Kingdom
-
Cornwell, United Kingdom
-
Derby, United Kingdom
-
Glasgow, United Kingdom
-
Ipswich, United Kingdom
-
Preston, United Kingdom
-
Worthing, United Kingdom
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:(main conditions)
- Female patients 18 to 75 years of age with metastatic breast cancer histologically/cytologically confirmed not amenable to curative surgery or radiotherapy and who have received at least two prior chemotherapy regimens including anthracyclines,taxanes,antimetabolite and vinca-alkaloid and are no longer candidate for these drugs,
- Karnofsky performance score of at least 70 %, adequate haematological, hepatic and renal functions and ECG without clinically relevant abnormality.
Exclusion Criteria:
- Concurrent serious uncontrolled medical disorder,
- known or clinical evidence of brain metastases or leptomeningeal involvement,
- pulmonary lymphangitis or symptomatic pleural effusion or symptomatic ascites,
- history of second primary malignancy,
- HIV infection, preexisting neuropathy,
- pregnancy or breast feeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: arm A: Vinflunine
Patients randomised in the test arm (arm A) received VFL at the dose of 280 mg/m² on day 1 of each cycle every 3 weeks, over a 20-minute intravenous (IV) infusion.
Cycles were repeated every 3 weeks.
|
280 mg/m2 on day 1 of each cycle every 3 weeks
Other Names:
|
Active Comparator: arm B: Alkylating agent of physician choice
Patients randomised in the control arm (arm B) received an alkylating agent used as a single agent which was available in the investigational center and was approved for the treatment of cancer in the country.
|
cyclophosphamide or melphalan or mitomycin C or thiotepa or cisplatin or carboplatin
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival
Time Frame: From baseline up to 3 years 1 month
|
The main endpoint of this study is overall survival defined as the time from randomisation to the date of death or last follow-up.
For patients who have not died, survival duration will be censored at the date of last contact or last follow-up or the date of last news.
|
From baseline up to 3 years 1 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease Control Rate (DCR)
Time Frame: From baseline up to 3 years 1 month
|
DCR was defined as the proportion of patients with Complete Response (CR), Partial Response (PR) and stable disease (SD), relative to the total number of patients in the analysed population.
|
From baseline up to 3 years 1 month
|
Progression Free Survival (PFS)
Time Frame: From baseline to cut-off date(27 August 2012), up to 3 years
|
PFS was defined as the time from randomisation to the first tumour progression or death due to any cause in the absence of previous documentation of objective tumour progression.
PFS was performed in the ITT and eligible populations every 6 weeks based on RECIST version 1.1.
For patients lost of follow up, or without a known record of progression or death, PFS was censored at the date of last tumour assessment or the date of last contact of a follow-up showing no progression which ever occured last.
|
From baseline to cut-off date(27 August 2012), up to 3 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Karim Keddad, MD, PhD, Institut de Recherche Pierre Fabre
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- L00070 IN 308 B0
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on vinflunine
-
Veeda OncologyBristol-Myers SquibbCompletedNon-Small Cell Lung CancerUnited States
-
SCRI Development Innovations, LLCBristol-Myers SquibbCompletedLung Cancer | Carcinoma, Small CellUnited States
-
Institute of Cancer Research, United KingdomSt George's Healthcare NHS TrustCompletedLocally-advanced or Metastatic Penile NeoplasmsUnited Kingdom
-
Associació per a la Recerca Oncologica, SpainUnknownUrothelium Transitional Cell CarcinomaSpain, Netherlands
-
SCRI Development Innovations, LLCBristol-Myers SquibbCompleted
-
Bristol-Myers SquibbTerminatedStomach CancerKorea, Republic of, Philippines, Malaysia
-
Bristol-Myers SquibbPierre Fabre MedicamentCompletedKidney Neoplasms | Transitional Cell Carcinoma | Bladder Cancer | Bladder Neoplasms | Ureter Neoplasms | Neoplasm, BladderUnited States, Spain, Italy, Canada, Indonesia, Singapore, Australia, Austria, France, Greece, Korea, Republic of, Philippines, Sweden, Switzerland, Thailand
-
Bristol-Myers SquibbCompleted
-
Pierre Fabre MedicamentBristol-Myers SquibbCompletedBladder Cancer | Bladder Neoplasms | Transitional Cell Carcinoma of the Urothelial TractCanada
-
Ligartis GmbHWithdrawn